

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

EDITOR

Neil Love, MD

FACULTY

Robert W Carlson, MD

William J Gradishar, MD

Enza Esposito Luke, RN, MSN, ONP

Steven Shak, MD

Eric P Winer, MD

*Additional comments by a woman with
breast cancer and her mother*



A Continuing Nursing Education Audio Series

STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and research leaders with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings.

ACCREDITATION STATEMENT

New Jersey State Nurses Association is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. This activity has been awarded 3.3 contact hours (approval number 6458-06/06-08).

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This book contains a continuing nursing education Post-test, and the corresponding website BreastCancerUpdate.com/Nurses includes links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of June 2006 through June 2007, participants should read the learning objectives and faculty disclosures, listen to the CDs and complete the Post-test and Evaluation form located in the back of this book or on the BreastCancerUpdate.com/Nurses website and mail or fax the Post-test and Evaluation form to Research To Practice.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at Info@ResearchToPractice.net, or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Breast Cancer®

U P D A T E

FACULTY AFFILIATIONS



Robert W Carlson, MD
Professor of Medicine
Division of Oncology and
Stanford Medical Informatics
Stanford University Medical Center
Stanford, California



Steven Shak, MD
Chief Medical Officer
Genomic Health Inc
Redwood City, California



William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois



Eric P Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts



Enza Esposito Luke, RN, MSN, ONP
Oncology Nurse Practitioner
Hematology/Oncology Medical
Group of Orange County
Orange, California

CONTENT VALIDATION AND DISCLOSURES

New Jersey State Nurses Association (NJSNA) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by NJSNA for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. NJSNA is committed to providing its learners with high-quality CNE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

Dr Carlson — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP; Contracted Research: AstraZeneca Pharmaceuticals LP. **Dr Gradishar** — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Sanofi-Aventis. **Ms Luke** — No financial interests or affiliations to disclose. **Dr Shak** — Salary: Genomic Health Inc; Patent Holder: Genomic Health Inc; Ownership Interest: Genomic Health Inc. **Dr Winer** — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following clinical content reviewers, Joanne Librie, RN, Bernadette Makar, MSN, ANP and Paula Mateo, RN, BA state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. New Jersey State Nurses Association (NJSNA), American Nurses Credentialing Center (ANCC), Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NJSNA, ANCC, Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology or Genomic Health Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Breast Cancer Update for Nurses — Issue 2, 2006**QUESTIONS (PLEASE CIRCLE ANSWER):**

- 1. Aromatase inhibitors can be effective in _____ patients with ER-positive breast cancer.**
 - a. Premenopausal
 - b. Postmenopausal
 - c. Both pre- and postmenopausal
- 2. In the trials comparing aromatase inhibitors to tamoxifen in the adjuvant setting in postmenopausal women, which intervention demonstrated a superior disease-free survival?**
 - a. Tamoxifen
 - b. Aromatase inhibitors
- 3. Which of the following adverse events occur less frequently with aromatase inhibitors than with tamoxifen?**
 - a. Endometrial cancer
 - b. Thromboembolic events
 - c. Fractures
 - d. Both a and b
- 4. Clinical trials have reported that adjuvant trastuzumab given to a patient with HER2-positive breast cancer reduces her risk of recurrence by approximately _____.**
 - a. 10 percent
 - b. 20 percent
 - c. 30 percent
 - d. 40 percent
 - e. 50 percent
- 5. Data from the adjuvant trials indicate that trastuzumab is effective in women with _____, HER2-positive breast cancer.**
 - a. Node-positive
 - b. Node-negative
 - c. Node-positive and node-negative
- 6. Patients with node-negative, ER-positive disease and a high recurrence score according to the Oncotype DX™ assay have been shown to benefit from adjuvant _____.**
 - a. Fulvestrant
 - b. Anastrozole
 - c. Chemotherapy
 - d. All of the above
- 7. In the ECOG trial comparing paclitaxel with or without bevacizumab in the metastatic setting, the addition of bevacizumab significantly _____ response rate and the duration of progression-free survival.**
 - a. Increased
 - b. Decreased
- 8. Which endocrine agent is given by intramuscular injection and has relatively few side effects?**
 - a. Tamoxifen
 - b. Anastrozole
 - c. Letrozole
 - d. Fulvestrant
- 9. In the pivotal trial comparing paclitaxel 175 mg/m² to nab paclitaxel 260 mg/m², the patients who received _____ had a significantly higher response rate and improved time to disease progression.**
 - a. Paclitaxel
 - b. Nab paclitaxel
- 10. Nab paclitaxel _____ require the use of steroid premedication.**
 - a. Does
 - b. Does not

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 2, 2006

The New Jersey State Nurses Association and Research To Practice respect and appreciate your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer. 5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings. 5 4 3 2 1
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse 5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings. 5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Robert W Carlson, MD	5 4 3 2 1	5 4 3 2 1
William J Gradishar, MD	5 4 3 2 1	5 4 3 2 1
Enza Esposito Luke, RN, MSN, ONP	5 4 3 2 1	5 4 3 2 1
Steven Shak, MD	5 4 3 2 1	5 4 3 2 1
Eric P Winer, MD	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
 Fulfilled my educational needs. 5 4 3 2 1
 Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits. Enhanced my current knowledge base.

Breast Cancer Update for Nurses — Issue 2, 2006

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....
.....

How committed are you to making these changes?

(5 = very committed; 1 = not at all committed)..... 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

.....
.....

Additional comments about this activity:

.....
.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree:

Organization: Specialty:

Address: ⓧ

City, State, Zip: ⓧ

Telephone: Fax: Email:

Signature: Date:

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

NBCU206

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Evaluation Form and mail or fax both to: Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131, FAX 305-377-9998. You may also complete the Post-test and Evaluation online at BreastCancerUpdate.com/Nurses.

Breast Cancer®

U P D A T E

Editor/CME Director	Neil Love, MD
Associate Editors	Richard Kaderman, PhD Kathryn Ault Ziel, PhD
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Associate Designer	Ben Belin
Graphic Designer	Jason Cunniss
Junior Designer	Shantia Daniel
Senior Production Editor	Alexis Oneca
Traffic Coordinator	Tere Sosa
Copy Editors	Dave Amber Joy Davis Mary DiNunzio Rosemary Hulce Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Patricia Kappes
Audio Production	Frank Cesarano
Technical Services	Arly Ledezma
Web Master	John Ribeiro
Editorial Assistants	Catherine Marshall Patricia McWhorter Christina Rodriguez Ginelle Suarez
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net
For CE Information	Email: CME@ResearchToPractice.net

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Breast Cancer[®]

U P D A T E

Copyright © 2006 Research To Practice.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.



Co-sponsored by New Jersey State Nurses Association and Research To Practice.

Last review date: June 2006
Release date: June 2006
Expiration date: June 2007
Estimated time to complete: 2.75 hours